This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) ~~Compounds~~ A compound of ~~the~~ formula I



I

~~in which~~ wherein

D ~~denotes~~ is an aromatic five-membered heterocyclic ring having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR^2, $N(R^2)_2$, NO_2, CN, $COOR^2$ or $CON(R^2)_2$,

X ~~denotes~~ is NR^3 or O,

R^1 ~~denotes~~ is H, Ar, Het, cycloalkyl or A, which ~~may be~~ is optionally substituted by OR^2, SR^2, $N(R^2)_2$, Ar, Het, cycloalkyl, CN, $COOR^2$ or $CON(R^2)_2$,

R^2 ~~denotes~~ is H, A, $-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

R^3 ~~denotes~~ is H or A,

W ~~denotes~~ is $-[C(R^3)_2]_n-$,

Y ~~denotes~~ is alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T ~~denotes~~ is a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocyclic ring having 0 to 4 N, O and/or S atoms, which ~~may be~~ is optionally unsubstituted or mono-, di- or trisubstituted by Hal, A,$-[C(R^3)_2]_n$-Ar, $-[C(R^3)_2]_n$-Het, $-[C(R^3)_2]_n$-cycloalkyl, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^2$, $CON(R^2)_2$, NR^2COA, $NR^2CON(R^2)_2$, NR^2SO_2A, COR^2, SO_2NR^2 and/or $S(O)_mA$ and/or carbonyl oxygen,

or $N(R^2)_2$

and, if Y = piperidine-1,4-diyl, also R^2 or cycloalkyl,

A ~~denotes~~ is unbranched or branched alkyl having 1-10 C ~~atoms~~, ~~in which~~ wherein one or two CH_2 groups ~~may be~~ are optionally replaced by O or S ~~atoms~~ and/or by -CH=CH- groups ~~and/or also~~ wherein 1-7 H atoms ~~may be~~ are optionally replaced by F,

Ar ~~denotes~~ is phenyl, naphthyl or biphenyl, each of which is, independently of one another, unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$, $S(O)_mA$, $-[C(R^3)_2]_n-COOR^{2'}$ or $-O-[C(R^3)_2]_o-COOR^{2'}$,

$R^{2'}$ ~~denotes~~ is H, A, $-[C(R^3)_2]_n-Ar'$, $-[C(R^3)_2]_n-Het'$, $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

$R^{2''}$ ~~denotes~~ is H, A, $-[C(R^3)_2]_n-Ar'$ or $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-N(R^3)_2$ or $-[C(R^3)_2]_n-OR^3$,

Ar' ~~denotes~~ is phenyl or benzyl, each of which is, independently of one another, unsubstituted or mono- or disubstituted by Hal or A,

Het ~~denotes~~ is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 4 N, O and/or S atoms, which ~~may be~~ is unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, $=N(R^3)_2$, Hal, A, $-[C(R^3)_2]_n-Ar$, $-[C(R^3)_2]_n-Het^1$, $-[C(R^3)_2]_n$-cycloalkyl, $-[C(R^3)_2]_n-OR^{2'}$, $-[C(R^3)_2]_n-N(R^{2'})_2$, NO_2, CN, $-[C(R^3)_2]_n-COOR^{2'}$, $-[C(R^3)_2]_n-CON(R^{2'})_2$, $-[C(R^3)_2]_n-NR^{2'}COA$, $NR^{2'}CON(R^{2'})_2$, $-[C(R^3)_2]_n-NR^{2'}SO_2A$, $COR^{2'}$, $SO_2NR^{2'}$ and/or $S(O)_mA$,

Het^1 ~~denotes~~ is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which ~~may be~~ is unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, $=N(R^3)_2$, Hal, A, $OR^{2''}$, $N(R^{2''})_2$, NO_2, CN, $COOR^{2''}$, $CON(R^{2''})_2$, $NR^{2''}COA$, $NR^{2''}CON(R^{2''})_2$, $NR^{2''}SO_2A$, $COR^{2''}$, $SO_2NR^{2''}$ and/or $S(O)_mA$,

Hal ~~denotes~~ is F, Cl, Br or I,

n ~~denotes~~ is 0, 1 or 2,

m ~~denotes~~ is 0, 1 or 2,

o ~~denotes~~ is 1, 2 or 3,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 2. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

D ~~denotes~~ is an aromatic five-membered heterocyclic ring having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 3. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

D ~~denotes~~ is a thienyl ring which is mono- or disubstituted by Hal,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 4. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

R^2 ~~denotes~~ is H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 5. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

R^1 ~~denotes~~ is H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 6. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

X ~~denotes~~ is NH or O,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 7. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

W ~~denotes~~ is $(CH_2)_n$,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 8. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

Y ~~denotes~~ is Ar-diyl or Het-diyl,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 9. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

T ~~denotes~~ is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N and/or O atoms, which ~~may be~~ is unsubstituted or mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 10. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

T ~~denotes~~ is a mono- or bicyclic saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is mono- or

disubstituted by carbonyl oxygen (=O),
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 11. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

T ~~denotes~~ is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 12. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

Ar ~~denotes~~ is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 13. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

D ~~denotes~~ is an aromatic five-membered heterocyclic ring having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

R^1 ~~denotes~~ is H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,

R^2 ~~denotes~~ is H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes NH or O,

W ~~denotes~~ is W $(CH_2)_n$,

Y ~~denotes~~ is Ar-diyl, pyridinediyl or piperidinediyl,

Ar ~~denotes~~ is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

T ~~denotes~~ is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[s] ~~and~~ or stereoisomer[s] thereof, ~~including~~ or a mixture[s] thereof in all ratios.

Claim 14. (Currently Amended) ~~Compounds~~ A compound according to Claim 1, ~~in which~~ wherein

D ~~denotes~~ is thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,

R^1 ~~denotes~~ is H or unsubstituted phenyl, thienyl or alkyl having 1-6 C atoms,

R^2 ~~denotes~~ is H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X ~~denotes~~ is NH or O,

W ~~denotes~~ is W $(CH_2)_n$,

Y ~~denotes~~ is Ar-diyl, pyridinediyl or piperidinediyl,

Ar ~~denotes~~ is phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2 or CN,

T ~~denotes~~ is piperidin-1-yl, pyrrolidin-1-yl, pyridinyl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazinyl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, each of which is unsubstituted or mono- or disubstituted by carbonyl oxygen,
or $N(R^2)_2$
and, if Y = piperidine-1,4-diyl, also R^2,

~~and~~ or a pharmaceutically ~~usable derivatives~~ acceptable salt, solvate[~~s~~] ~~and~~ or stereoisomer[~~s~~] thereof, ~~including~~ or a mixture[~~s~~] thereof in all ratios.

Claim 15. (Currently Amended) ~~Compounds~~ A compound according to Claim 1 ~~selected from the group~~ which is

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-3-methylphenyl]valeramide,

2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]acetamide,

(R)-2-[3-(5-bromothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-bromofuran-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-phenylacetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-(thiophen-2-yl)acetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(2-oxopiperidin-1-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(2-oxo-1*H*-pyrazin-1-yl)-phenyl]valeramide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[2-oxo-3,4,5,6-tetrahydro-[1,2']bipyridinyl-5'-yl]valeramide,

(S)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]-2-phenylacetamide,

(R)-2-[3-(5-chlorothiophen-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenylmethyl]valeramide,

(R)-2-[3-(5-chlorothiazol-2-yl)ureido]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]valeramide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[[4-(3-oxo-morpholin-4-yl)phenyl]valeramide,

(R)-2-[*N*-(5-chlorothiophen-2-yl)carbamoyloxy]-*N*-[*C*-(3,4,5,6-tetrahydro-2*H*-[1,4']bipyridinyl-4-yl)methyl]valeramide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[1-isopropyl-piperidin-4-ylmethyl]-2-phenylacetamide,

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-[[4-(morpholin-4-yl)phenyl]valeramide; or

(R)-2-[N-(5-chlorothiophen-2-yl)carbamoyloxy]-N-(4-dimethylamino-phenyl)-2-phenylacetamide,

and or a pharmaceutically usable derivatives acceptable salt, solvate[s] and or stereoisomer[s] thereof, including or a mixture[s] thereof in all ratios.

Claim 16. (Currently Amended) Process A process for the preparation of compounds a compound of the formula I according to Claim 1 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that comprising

a) reacting a compound of the formula II



II

in which wherein

R^1, W, X, Y and T have the meaning indicated in Claim 1,

is reacted with a compound of the formula III

D-N=C=O III

in which wherein

D has the meaning indicated in Claim 1,

or

b) reacting a compound of ~~the~~ formula IV

$H_2N\text{-}W\text{-}Y\text{-}T$ IV

~~in which~~ wherein W, Y and T have the meaning indicated in Claim 1,

~~is reacted~~ with a compound of ~~the~~ formula V



V

~~in which~~ wherein

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R^1, X and D have the meanings indicated in Claim 1,

and/or

optionally converting a base or acid of ~~the~~ formula I ~~is converted~~ into one of its salts.

Claim 17. (Currently Amended) ~~Compounds of the formula I according to Claim 1 as inhibitors of~~ A method of inhibiting coagulation factor Xa comprising contacting said coagulation factor Xa with a compound according to claim 1.

Claim 18. (Currently Amended) ~~Compounds of the formula I according to Claim 1 as inhibitors of~~ A method of inhibiting coagulation factor VIIa comprising contacting said coagulation factor VIIa with a compound according to claim 1.

Claim 19. (Currently Amended) ~~Medicaments~~ A pharmaceutical composition comprising at least one compound ~~of the formula I~~ according to Claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants~~ and a pharmaceutically

acceptable carrier.

Claim 20. (Currently Amended) ~~Medicamens~~ A pharmaceutical composition comprising at least one compound ~~of the formula I~~ according to Claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and ~~at least one further medicament active ingredient~~ an excipient, adjuvant, or vitamin.

Claim 21. (Withdrawn-Currently Amended) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament~~ A method for the treatment of thromboses, myocardial infarction,. arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases comprising administering to a subject in need thereof a compound of claim 1.

Claim 22. (Currently Amended) ~~Set (kit) consisting of separate packs of~~ A set or a kit comprising

(a) an effective amount of a compound ~~of the formula I~~ according to Claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~

and

(b) an effective amount of ~~a further medicament active ingredient~~ an excipient, adjuvant, or vitamin.

Claim 23. (Withdrawn) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament~~ A method for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases comprising administering to a subject in need thereof a pharmaceutical composition of claim 19. ~~, in combination with at least one further medicament active ingredient.~~